Silexion Therapeutics Corp (NASDAQ:SLXN) Short Interest Update

Silexion Therapeutics Corp (NASDAQ:SLXN) was the recipient of a large growth in short interest in the month of July. As of July 31st, there was short interest totaling 21,284 shares, a growth of 62.6% from the July 15th total of 13,090 shares. Currently, 5.3% of the shares of the company are short sold. Based on an average daily volume of 111,194 shares, the short-interest ratio is presently 0.2 days.

Institutional Trading of Silexion Therapeutics

A hedge fund recently bought a new position in Silexion Therapeutics stock. Ancora Advisors LLC acquired a new stake in Silexion Therapeutics Corp (NASDAQ:SLXN) during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 30,000 shares of the company’s stock, valued at approximately $31,000. Ancora Advisors LLC owned about 7.14% of Silexion Therapeutics at the end of the most recent reporting period. 10.95% of the stock is currently owned by institutional investors and hedge funds.

Silexion Therapeutics Stock Down 0.9%

Shares of SLXN traded down $0.00 during trading hours on Tuesday, hitting $0.42. 304,435 shares of the company were exchanged, compared to its average volume of 329,362. Silexion Therapeutics has a fifty-two week low of $0.37 and a fifty-two week high of $80.00. The company has a market cap of $359,652.00, a price-to-earnings ratio of -0.01 and a beta of -0.25. The firm’s fifty day moving average is $2.33 and its 200 day moving average is $8.38.

Silexion Therapeutics (NASDAQ:SLXN) last posted its quarterly earnings results on Friday, August 14th. The company reported ($5.17) EPS for the quarter, beating analysts’ consensus estimates of ($21.20) by $16.03. Analysts anticipate that Silexion Therapeutics will post -45.5 EPS for the current year.

Analyst Upgrades and Downgrades

SLXN has been the topic of a number of analyst reports. Maxim Group lowered shares of Silexion Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, July 29th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Silexion Therapeutics in a research report on Monday, June 15th. One analyst has rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold”.

About Silexion Therapeutics

Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor.